Scott Wadler

Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group

Maurie Markman, Brian N. Bundy, David S. Alberts et al. · Journal of Clinical Oncology · 2001 · 1.1K citations

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

Sandra M. Swain, Fredrick S. Whaley, Mirjam C. Gerber et al. · Journal of Clinical Oncology · 1997 · 647 citations

Recommended Guidelines for the Treatment of Cancer Treatment-Induced Diarrhea

Al B. Benson, Jaffer A. Ajani, Robert B. Catalano et al. · Journal of Clinical Oncology · 2004 · 622 citations

Mortality Associated With Irinotecan Plus Bolus Fluorouracil/Leucovorin: Summary Findings of an Independent Panel

Mace L. Rothenberg, Neal J. Meropol, Elizabeth Poplin et al. · Journal of Clinical Oncology · 2001 · 425 citations

Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study

Leonard B. Saltz, Heinz‐Josef Lenz, Hedy L. Kindler et al. · Journal of Clinical Oncology · 2007 · 424 citations · Full text